David H. Crean, PhD, Managing Director and head of our Life Sciences and Healthcare Practice Group provides his thoughts and guidance to entrepreneurs, founders and business owners in the life sciences sector on what he has seen as successful pitches to investors and strategic companies in the initial pitches of their company and technology. By providing as much of the information noted below during the process, we believe that you can improve the probability and chances of landing a transaction that supports company growth or exit strategies. David has also previously authored related articles on this topic that can be viewed here and here. Happy to clarify any topic if needed.(more…)
San Diego, CA and Flagstaff, AZ, April 12, 2018: — Symple Surgical, Inc., a privately-held, early-stage medical device company focused on developing novel therapeutic technologies using microwave technology for treatment of life-threatening chronic conditions, is pleased to the announce that they have retained Objective Capital Partners as their exclusive financial advisor. Objective Capital Partners, a middle-market Investment Banking firm located in Southern California and focused on mergers & acquisitions (M&A), strategic advisory, capital financing and valuation services, will seek to identify strategic partnerships and financial investors for the Company to progress their lead product Grizzly™ targeting pre-cancerous cells in the elimination of Barrett's Esophagus and Esophageal Adenocarcinoma, the fastest growing cancer worldwide.
Barrett’s Esophagus (BE) is a premalignant condition caused by stomach acid or gastrointestinal reflux disease (GERD) mutating healthy cells in the lower esophagus into Barrett’s cells. Approximately 90% of Esophageal Adenocarcinoma (EAC) patients do not receive a prior diagnosis of Barrett’s Esophagus (BE). BE affect’s more than 12 million American adults, and is associated with a 30-fold increased risk of developing EAC. This new treatment will provide an alternative to the Radiofrequency Ablation Technology (“RFA”) and cryoablation technologies currently in use for treatment of BE thereby reducing the number of episodes of treatment and providing unparalleled user control for adequate cell removal.(more…)
San Diego Business Journal Health Care Heros Award
San Diego, March 1, 2018 – The San Diego Business Journal’s 2018 Health Care Heroes Awards chose Objective Capital Partners’ David H. Crean, Ph.D. from among the finalists to receive the Health Care Hero Award for Company Executive for his role in healthcare innovation and support.
Leading Objective Capital Partners’ Life Sciences & Healthcare Investment Banking Practice, David leverages more than 20 years of life sciences R&D and corporate development experience. In his Managing Director role, David helps companies secure growth capital, establish strategic partnerships, and achieve exit transactions.(more…)
The Alliance of Merger & Acquisition Advisors® (AM&AA)
San Diego, January 30, 2018 — Objective Capital Partners, a middle-market M&A Advisory Firm located in Southern California, is pleased to announce that David H. Crean, Ph.D., Managing Director of the firm’s thriving Life Sciences and Healthcare practice, has been selected as the winner of the 2017 Thought Leader of the Year Award by The Alliance of Merger & Acquisition Advisors® (AM&AA).
The AM&AA recognized that “David’s thought leadership is materially expanding the investment banker’s role in serving life sciences companies and providing these companies with a highly attractive, non-diluting alternative to hard-to-secure venture capital financing.”
“We are observing life sciences and healthcare companies increasing engaging specialized investment banking teams with deep industry experience to gain a strategic advantage,” said Trever Acers, Managing Director at Objective Capital Partners. “Specialized professionals such as David and his team members at Objective Capital are engaged by experienced Life Sciences executives to significantly improve the value, probability and speed of their M&A, strategic partnering, and growth capital objectives. David is at the forefront of this change, leveraging his decades of industry experience with best-in-class investment banking capabilities to provide CEO with highly actionable strategic guidance."(more…)
Objective Capital Partners has expertise in four industry sectors: Business Services, Consumer, Life Sciences & Healthcare, and Technology. As part of our ongoing efforts in the Life Sciences and Healthcare space, we have developed specific expertise in Life Science Tools. In fact, we recently closed an interesting transaction in the life sciences services space.(more…)
Objective Capital’s David H. Crean to be Guest Panelist at ACG Orange County's CEO Signature Event on November 15, 2017
San Diego, November 6, 2017 — Objective Capital Partners, a middle-market M&A Advisory Firm located in Southern California, is pleased to announce that David H. Crean, Ph.D., one of its Managing Directors who heads its thriving life science and healthcare practice, will be a guest panelist speaker at ACG Orange County’s CEO Signature Event entitled SoCal Capital Summit on November 15, 2017. Dr. Crean and the fellow panelists will address M&A Healthcare Trends and Opportunities. He will be joined by Greg Cunniff, CFO, NVISION Eye Centers, and Steven Shill, Partner and National Healthcare Practice Leader at BDO.(more…)
Objective Capital Partners Acted as Financial Advisor to Practicing Excellence
San Diego, CA- September 25, 2017 - Objective Capital Partners, a leading M&A investment banking firm specializing in middle market M&A, healthcare & life sciences and valuation advisory services, is pleased to announce the successful closing of one of its advisory engagements with Practicing Excellence upon its strategic alliance with and investment from NRC Health. Practicing Excellence, the developer of an online skill-building platform, connects clinicians to practical, evidence-based, colleague-tested tools designed to enhance the delivery of patient care and improve the overall physician experience.(more…)
Start-up and Emerging Companies to Present at BIO2017
San Diego, CA- June 12, 2017 - Objective Capital Partners, a leading M&A investment banking firm specializing in middle-market M&A and capital raise, healthcare & life sciences and valuation advisory services, is pleased to announce that one of its Managing Directors, David H. Crean, Ph.D., will serve as a Judge for company finalists during live presentations as part of BIO 2017 Start-Up Stadium on June 20-22, 2017 in San Diego, CA. As the world’s largest biotechnology event, the BIO International Convention provides several specialized opportunities geared towards start-up and emerging companies. The Start-Up Stadium was designed to provide start-up companies with the opportunity to engage key members of the investment community, venture philanthropy groups, and BIO attendees.(more…)
Objective Capital’s Dr. David Crean to Moderate M&A
Panel Discussion for ACG San Diego on June 20, 2017
San Diego, CA- June 6, 2017 - Objective Capital Partners, a leading M&A investment banking firm specializing in middle market M&A and capital raise, healthcare & life sciences and valuation advisory services, is pleased to announce that one of its Managing Directors, David H. Crean, Ph.D., will serve as Moderator for ACG San Diego’s Hot Topics in Life Sciences M&A, June 20, 2017 at Lomas Santa Fe Country Club, Solana Beach, CA from 7-9 AM.(more…)
Panel Discussion on Life Sciences Transactions, Research Collaborations, and Licensing Models to be presented on June 17, 2017
San Diego, CA- May 31, 2017 - Objective Capital Partners, a leading M&A investment banking firm specializing in middle market M&A and capital raise, healthcare & life sciences and valuation advisory services, is pleased to announce that one of its Managing Directors, David H. Crean, Ph.D., will serve as a panel member and address legal professionals at the 5th Annual World Life Sciences Conference, June 16–17, 2017 at the Westin San Diego Gaslamp Quarter, San Diego, CA. The conference is presented by the International Bar Association (IBA), a global voice for the legal profession. The event will feature dynamic roundtable sessions covering the hottest topics and the latest developments from across the different sectors of the Life Science Industry.(more…)
This article is provided for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC makes no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.